Q: Today we are seeing another short seller, Citron Research, issue a report condemning Cronos whose reporting is being compared to disclosures by Canapy and Tilray.
Often, research assessments have been based on subjective judgment. What recourse do shareowners have to ensure there is accuracy? Are these firms subjective to recourse or penalties should their reports be issued for personal gain? Are there cases of class action lawsuits?
https://citronresearch.com/wp-content/uploads/2018/08/Cronos-The-Dark-Side-of-The-Cannabis-Space.pdf
Often, research assessments have been based on subjective judgment. What recourse do shareowners have to ensure there is accuracy? Are these firms subjective to recourse or penalties should their reports be issued for personal gain? Are there cases of class action lawsuits?
https://citronresearch.com/wp-content/uploads/2018/08/Cronos-The-Dark-Side-of-The-Cannabis-Space.pdf